Ankylosing Spondylitis, Crohn's Disease, Psoriasis, Rheumatoid Arthritis
Conditions
Keywords
TNF alpha antagonists, infections, lymphoma, safety
Brief summary
The RATIO registry is a French registry designed by a multidisciplinary group to collect data on opportunistic and severe bacterial infections and lymphoma in patients treated with TNF-a antagonists ( infliximab, etanercept and adalimumab). A total of 486 medical units in metropolitan France participate in the RATIO registry. All diagnosis are retained after validation by 2 qualified infectious disease or haematologist physicians (on the basis of the standardized case report form, the hospitalisation summary, and the microbiological and radiological results). Risk factors for developing these conditions when treated by TNF-a antagonists will be identified in a case control study. Incidence of these diseases will be calculated.
Interventions
DRUGTNF-alpha antagonists
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
0 Years to No maximum
Healthy volunteers
No
Inclusion criteria
for cases: * past or current treatement with TNF-a antagonists * either lymphoma severe bacterial infection opportunistic infection Inclusion Criteria for controls: * matched with cases by gender, age (+/- 5 years), underlying disease (rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, or psoriasis) * past or current treatement with TNF-a antagonists * no lymphoma, severe bacterial infection, opportunistic infection (same as case)
Exclusion criteria
* none
Countries
France
Contacts
Primary ContactFlorence TUBACH, MD
Outcome results
None listed